Fed. Circ. Backs Pfizer's Patent For Cancer Drug Sutent
Pfizer Inc. secured a win Wednesday in its bid to block Mylan Inc. from introducing a generic version of the blockbuster cancer drug Sutent when a Federal Circuit panel affirmed that...To view the full article, register now.
Already a subscriber? Click here to view full article